- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07601334
Safety and Activity of HF50 in Patients With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of HF50 in Patients With Advanced Solid Tumors
A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.
Обзор исследования
Подробное описание
This is an open-label, dose-escalation and dose-expansion, multiple-dose, phase 1 study evaluating HF50 monotherapy in participants with advanced solid tumors. HF50 is an innovative liposome-encapsulated T-cell engager designed to redirect T-cells to tumor cells by presenting both tumor-associated antigen (e.g., HER2) and CD3 targeting moieties on the liposome surface. Simultaneously, HF50 delivers an encapsulated TLR7/8 agonist to activate innate immunity and remodel the tumor immune microenvironment, creating a synergistic anti-tumor immune response.The primary objective is to evaluate the safety and tolerability of HF50 and to determine the recommended Phase 2 dose (RP2D). HF50 will be administered as an intravenous (IV) infusion. The study will also assess the pharmacokinetic (PK) profile, immunogenicity, and preliminary anti-tumor activity of HF50. Additionally, the study will explore the impact of HF50 on the immune microenvironment and changes in peripheral blood cytokines and immune cells to better understand its biological effects.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 1
Контакты и местонахождение
Контакты исследования
- Имя: xun Wang
- Номер телефона: +86-571-86961869
- Электронная почта: wangxun717416@gmail.com
Места учебы
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Китай, 100021
- Еще не набирают
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Контакт:
- FEI MA, MD,PhD
-
Главный следователь:
- FEI MA, MD,PhD
-
-
Guangdong
-
Guangzhou, Guangdong, Китай, 510120
- Рекрутинг
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
Главный следователь:
- Jing Li, MD, PhD
-
Главный следователь:
- Qiong Yang, MD, PhD
-
Контакт:
- HERUI YAO, MD,PhD
- Номер телефона: +8613500018020
- Электронная почта: yaohrsysu@163.com
-
Главный следователь:
- HERUI YAO, MD,PhD
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Voluntary participation: Capable of giving signed informed consent and able to comply with all study-related procedures.
- Age: Adults >= 18 years of age at the time of signing informed consent; male or female.
- Disease Status: Participants with histologically or cytologically confirmed advanced solid tumors that are unresectable or metastatic, who have failed or are intolerant to standard therapies, or for whom no effective therapy currently exists. Examples include HER2-expressing gynecological tumors and recurrent ovarian clear cell carcinoma after failure of platinum-based chemotherapy.
- Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
- Life Expectancy: Anticipated survival of no less than 6 months.
- Measurable Disease: At least one measurable lesion according to RECIST v1.1 definitions.
- Organ and Bone Marrow Function:
Bone Marrow Reserve: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, lymphocyte count >= 1.0 x 10^9/L, platelet count >= 90 x 10^9/L, and hemoglobin >= 9.0 g/dL (no blood transfusion or hematopoietic stimulators within 14 days).
Coagulation Function: Activated partial thromboplastin time (APTT) <= 1.5 x ULN, and International Normalized Ratio (INR) <= 1.5.
Liver Function: Total bilirubin (TBIL) <= 1.5 x ULN, and ALT and AST <= 2.5 x ULN. For participants with liver metastases: ALT and AST <= 5 x ULN, and TBIL <= 3 x ULN.
Renal Function: Creatinine clearance >= 50 mL/min (calculated using the Cockcroft-Gault formula).
- Contraception: Participants of reproductive potential (including males) must agree to use effective contraception from study entry through 6 months after the last dose. Female participants of childbearing potential must have a negative serum pregnancy test during screening and prior to the first dose.
Exclusion Criteria:
- Autoimmune Disease: Any active autoimmune disease or history of autoimmune disease deemed unsuitable by the investigator. Exceptions include skin conditions not requiring systemic treatment (e.g., eczema < 10% of body surface area, vitiligo, psoriasis, alopecia) and resolved childhood asthma.
- Corticosteroids/Immunosuppressants: Current use of immunosuppressants or systemic corticosteroids (> 10 mg/day prednisone or equivalent) within 4 weeks prior to the first dose. Topical steroid use is permitted.
- Prior Anti-tumor Therapy: Receipt of systemic chemotherapy, radiotherapy, targeted therapy, or immunotherapy within 2 weeks prior to dosing (4 weeks for nitrosoureas or mitomycin C); or other therapies (endocrine therapy, TCM, localized palliative radiotherapy) within 2 weeks.
- CNS Metastasis: Clinically symptomatic brain or meningeal metastases. Participants with treated brain metastases are eligible if radiographic stability is maintained for >= 28 days, systemic steroids have been discontinued for > 14 days, and the participant is asymptomatic.
- Toxicity Recovery: Failure to recover from all adverse events of prior therapies to <= Grade 1 (NCI CTCAE v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, or stable hypothyroidism on hormone replacement.
- Cardiovascular History: Including thromboembolic events within 3 months; NYHA Class III to IV congestive heart failure; acute coronary syndrome, aortic dissection, stroke, or other Grade >= 3 cardiovascular events within 6 months; or uncontrolled hypertension (SBP > 160 mmHg or DBP > 100 mmHg).
- Infection: Active infection or unexplained fever > 38.5 degrees C within 1 week prior to the first dose (tumor-related fever is permitted per investigator judgment).
- Viral Infection: HIV infection, active HBV (HBV DNA > ULN), or active HCV (HCV RNA > ULN).
- Gastrointestinal Symptoms: Significant digestive system symptoms or other factors requiring intervention within 4 weeks prior to the first dose.
- Pregnancy/Lactation: Female participants who are pregnant or breastfeeding.
- Other: Any other serious systemic disease or reason that, in the investigator's opinion, makes the participant unsuitable for the study.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: HF50
HF50 monotherapy |
HF50 is an innovative liposome-encapsulated bifunctional therapeutic designed to redirect T-cells to HER2-expressing tumor cells while simultaneously activating innate immunity through TLR7/8 agonism. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of Participants with Dose Limiting Toxicities (DLT)
Временное ограничение: 28 days after the first dose (C1D1) for each dose cohort.
|
The number of participants experiencing dose-limiting toxicities (DLTs) during the DLT evaluation period to determine the maximum tolerated dose (MTD). |
28 days after the first dose (C1D1) for each dose cohort.
|
|
Incidence of Adverse Events (AEs)
Временное ограничение: From first dose to 28 days after the last dose.
|
The number and percentage of participants experiencing adverse events (AEs), graded according to NCI-CTCAE v5.0 |
From first dose to 28 days after the last dose.
|
|
Recommended Phase II Dose (RP2D) of HF50
Временное ограничение: At the end of dose escalation (assessed up to 1 year)
|
RP2D will be determined based on safety, tolerability, and pharmacokinetics data collected during the dose escalation phase. |
At the end of dose escalation (assessed up to 1 year)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Objective Response Rate (ORR)
Временное ограничение: Up to 2 years
|
Proportion of participants achieving a complete response (CR) or partial response (PR) based on RECIST v1.1 criteria. |
Up to 2 years
|
|
Duration of Response (DOR)
Временное ограничение: Up to 2 years
|
Time from the first documented response (CR or PR) to disease progression or death. |
Up to 2 years
|
|
Disease Control Rate (DCR)
Временное ограничение: Up to 2 years
|
Proportion of participants achieving CR, PR, or stable disease (SD) based on RECIST v1.1. |
Up to 2 years
|
|
Progression-Free Survival (PFS)
Временное ограничение: Up to 2 years
|
Time from the first dose to disease progression or death. |
Up to 2 years
|
|
Overall Survival (OS)
Временное ограничение: Up to 2 years
|
Time from the first dose to death from any cause. |
Up to 2 years
|
|
Pharmacokinetic Parameter - Cmax
Временное ограничение: Up to 2 years
|
Maximum plasma concentration (Cmax) of HF50 will be assessed following single and multiple dosing. |
Up to 2 years
|
|
Pharmacokinetic Parameter - Tmax
Временное ограничение: Up to 2 years
|
Time to maximum plasma concentration (Tmax) of HF50 will be assessed following single and multiple dosing. |
Up to 2 years
|
|
Pharmacokinetic Parameter - AUC (Area Under the Curve)
Временное ограничение: Up to 2 years
|
AUC0-t and AUC0-inf will be evaluated to determine systemic exposure to HF50. |
Up to 2 years
|
|
Pharmacokinetic Parameter - Half-life (t1/2)
Временное ограничение: Up to 2 years
|
The terminal elimination half-life (t1/2) of HF50 will be calculated. |
Up to 2 years
|
Соавторы и исследователи
Следователи
- Главный следователь: HERUI YAO, MD,PhD, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
- HF50-102
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .